Holen Sie sich die Stockscreener-App
25.43
0.16%
0.04
Handel nachbörslich:
25.43
Schlusskurs vom Vortag:
$25.39
Offen:
$25.34
24-Stunden-Volumen:
1.28M
Relative Volume:
1.29
Marktkapitalisierung:
$1.69B
Einnahmen:
$8.30M
Nettoeinkommen (Verlust:
$-150.22M
KGV:
-9.6326
EPS:
-2.64
Netto-Cashflow:
$-122.93M
1W Leistung:
-5.32%
1M Leistung:
-17.03%
6M Leistung:
-40.25%
1J Leistung:
-2.12%
1-Tages-Spanne:
$24.43
$25.71
1-Wochen-Bereich:
$24.43
$27.37
52-Wochen-Spanne:
$24.43
$53.18
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Firmenname
Celldex Therapeutics Inc
Sektor
Branche
Telefon
908-200-7500
Adresse
53 FRONTAGE ROAD, HAMPTON
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-07 | Eingeleitet | Citigroup | Buy |
| 2024-09-30 | Eingeleitet | Goldman | Neutral |
| 2024-09-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Eingeleitet | Stifel | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-20 | Eingeleitet | TD Cowen | Outperform |
| 2023-11-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Eingeleitet | Wells Fargo | Underweight |
| 2021-09-17 | Eingeleitet | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-22 | Eingeleitet | Guggenheim | Buy |
| 2020-02-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-07 | Eingeleitet | Aegis Capital | Buy |
| 2016-03-08 | Herabstufung | Jefferies | Buy → Hold |
| 2016-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2016-03-07 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-08-11 | Bestätigt | Brean Capital | Buy |
| 2015-08-11 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-11 | Bestätigt | ROTH Capital | Buy |
| 2015-06-02 | Bestätigt | WBB Securities | Strong Buy |
| 2014-11-17 | Bestätigt | ROTH Capital | Buy |
| 2014-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2013-07-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-03-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2013-01-10 | Bestätigt | Cantor Fitzgerald | Buy |
| 2012-10-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-09-14 | Bestätigt | Cantor Fitzgerald | Buy |
Alle ansehen
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month LowTime to Sell? - MarketBeat
Celldex stock touches 52-week low at $25.04 amid market shifts - Investing.com India
Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market - Seeking Alpha
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Emerald Advisers LLC Has $15.51 Million Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Evommune raises $115M to accelerate immune drug tests - Yahoo Finance
Market reaction to Intellia data suggests perfection remains bar for gene editing - BioCentury
Celldex Therapeutics (NASDAQ:CLDX) Trading Down 6%What's Next? - MarketBeat
Prurigo Nodularis Pipeline Update 2024: FDA Approvals, - openPR
Celldex shares hold as analyst maintains Buy rating By Investing.com - Investing.com UK
Celldex selloff creates buying opportunity, says Guggenheim - Yahoo Finance
Celldex shares gain as TD Cowen affirms Buy rating on robust Ph2 data - Investing.com UK
Analyst Expectations For Celldex Therapeutics's Future - Benzinga
HC Wainwright Reaffirms "Buy" Rating for Celldex Therapeutics (NASDAQ:CLDX) - MarketBeat
Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) pulls back 6.1% this week, but still delivers shareholders fantastic 57% CAGR over 5 years - Yahoo Finance
Novo Holdings A S Grows Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria - ForexTV.com
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 - The Manila Times
Celldex Therapeutics (CLDX): A Top Small-Cap Growth Stock with Promising Clinical Results - Insider Monkey
8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
TSX Global Gold Index (TTGD) QuotePress Release - The Globe and Mail
Personalized Cancer Vaccines Market Set for Major Growth During - openPR
Tyrosine Protein Kinase Receptor TYRO3 Market Report to 2032 -Celldex Therapeutics Inc, Elsalys Biotech SAS, Ignyta Inc, – IndiaPolitics.com - IndiaPolitics.com
Celldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap Stocks - Insider Monkey
Chronic Spontaneous Urticaria Market Forecasted to Surge - openPR
Celldex Therapeutics Inc. (CLDX) is a good investment, but the stock may be undervalued - US Post News
Investor’s Delight: Celldex Therapeutics Inc. (CLDX) Closes Weak at 30.28, Down -3.32 - The Dwinnex
Examining the Potential Price Growth of Celldex Therapeutics Inc. (CLDX) - Knox Daily
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
10 Most Promising Small-Cap Stocks According to Hedge Funds - Insider Monkey
A company insider recently sold 17,172 shares of Celldex Therapeutics Inc. [CLDX]. Should You Sale? - Knox Daily
A History of Outperforming Analyst Forecasts and Beating the Odds: Celldex Therapeutics Inc. (CLDX) - SETE News
Sarepta Therapeutics Inc [SRPT] Chief Financial Officer makes an insider purchase of 5,985 shares worth 0.82 million. - Knox Daily
Antibody Drug Conjugates Industry Report (2024-2032) - GlobeNewswire
Antibody Drug Conjugates Industry Report (2024-2032) Featuring Profiles the Top 13 PlayersADC Therapeutics, Astellas Pharma, AstraZeneca, Celldex Therapeutics, Roche & More - Yahoo Finance
The Potential Rise in the Price of Celldex Therapeutics Inc. (CLDX) following insiders activity - Knox Daily
Quarterly Metrics: Quick and Current Ratios for Celldex Therapeutics Inc. (CLDX) - The Dwinnex
Antibody Drug Conjugates Market Size Potential to Reach USD 39 Billion by 2032 By IMIR Market Research Pvt. Ltd. - Yahoo Finance
Is it possible to buy Celldex Therapeutics Inc.(CLDX) shares at a good price now? - US Post News
Celldex Therapeutics (NASDAQ:CLDX) Coverage Initiated by Analysts at Citigroup - MarketBeat
Citi cites sell-off in Celldex stock as overblown, highlights strong drug outlook - Investing.com UK
Oligodendroglioma Treatment Market Research Covers, Future Trends and Deep Analysis (2024-2034) - Colormagenta
Renaissance Technologies LLC Lowers Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Anaplastic Oligoastrocytoma Drug Market Review: All Eyes on 2024 Outlook - Bacterial Vaccines Market with ...
CLDX Stock Sees Decline of Approximately -16.13% in Last Five Days - Knox Daily
Celldex Therapeutics Inc. (CLDX) Stock: A Year of Highs and Lows - The InvestChronicle
Celldex Therapeutics (NASDAQ:CLDX) Trading Down 5% - MarketBeat
Celldex Therapeutics Insiders Sold US$2.1m Of Shares Suggesting Hesitancy - Simply Wall St
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Holdings Lifted by Algert Global LLC - MarketBeat
Finanzdaten der Celldex Therapeutics Inc-Aktie (CLDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):